Healthcare Industry News: Rainbow SET Pulse CO-Oximetry
News Release - September 22, 2009
Physio-Control Receives Market Approval from Health Canada for LIFEPAK(R) 15 Monitor/DefibrillatorREDMOND, Wash.--(HSMN NewsFeed)--Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc., (NYSE: MDT ) announced today it received approval by Health Canada to market the LIFEPAK 15 monitor/defibrillator within Canada. Official license notification was received on Sept. 1, 2009.
Physio-Control was granted CE mark in January 2009, certifying compliance with the European Union Medical Device Directive and began its U.S. market release of the LIFEPAK 15 monitor/defibrillator in March 2009.
The LIFEPAK 15 monitor/defibrillator builds on a 54-year Physio-Control heritage of providing innovative, reliable equipment to lifesaving teams around the world. With an all-new product platform, it delivers best-in-class clinical and operational innovations and raises the bar on the legendary LIFEPAK(R) standard for durability.
Clinically innovative, the LIFEPAK 15 provides the widest range of energy dosing up to 360 joules, and the broadest selection of monitoring options available. It continues Physio-Control’s legacy of industry firsts as the first monitor/defibrillator to integrate Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) technology for the noninvasive detection of carboxyhemoglobin (carbon monoxide in the blood; the leading cause of poisoning death in industrialized countries1) and methemoglobin in the blood (which may result from exposure to certain chemicals and drugs).
The design focuses on several key operational innovations which include the largest color screen on the market, with a one-touch button that flips the screen to high-contrast SunVue(TM) mode for easy viewing in sunlight; along with 10 times the processing speed and three times the battery life of its predecessor. Needed for the harshest rescue environments, Physio-Control developed the LIFEPAK 15 to be tougher than any other monitor/defibrillator on the market. For current LIFEPAK customers, this model reduces transition costs, with a user interface that complements the market-leading LIFEPAK 12 defibrillator/monitor. Emergency care providers are able to work with a mixed fleet of LIFEPAK monitors, and transition their equipment when budgets allow—enabling them to save on critical operational costs and minimize their overall training resources.
“Physio-Control has been developing and refining monitoring and defibrillation technology for more than 50 years. With the latest approval for distribution by Health Canada the LIFEPAK 15 continues to build momentum in the marketplace and is setting the new standard for emergency care products,” said Brian Webster, president of Physio-Control. “The ‘15’ has already been put into use by multiple leading EMS systems around the world.”
Masimo Founder and CEO, Joe E. Kiani, stated, “The LIFEPAK 15 monitor with Masimo Rainbow SET Pulse CO-Oximetry technology represents a significant advancement for emergency first responders who provide lifesaving care and treatment to combat a range of silent killers. The combination of a defibrillator with noninvasive carboxyhemoglobin (SpCO) and methemoglobin (SpMet) monitoring capabilities means that more cases of potentially life-threatening conditions may be detected and treated earlier to improve patient safety, outcomes and recoveries.”
Physio-Control, a wholly-owned subsidiary of Medtronic, is located in Redmond, Wash. Physio-Control pioneered defibrillation technology more than 54 years ago. With nearly 800,000 LIFEPAK(R) defibrillators distributed worldwide, the company is the world’s leading provider of external defibrillation and monitoring technology for the treatment of sudden cardiac arrest and other cardio-respiratory emergencies. To find out more about Physio-Control, go to www.physio-control.com or call 1-800-442-1142.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Masimo (NASDAQ: MASI ) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-OximetryTM, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com. PR Contact: Dana Banks, Masimo Corporation, 949-297-7348.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.
1 Omaye ST. (Nov 2002). "Metabolic modulation of carbon monoxide toxicity". Toxicology 180 (2): 139–50.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.